SK Biopharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for Cenobamate

Application seeks indication for primary generalized tonic-clonic (PGTC) seizures and expansion of existing focal-onset seizure indication to pediatric patients - Submission supported by results from a global Phase 3 trial evaluating the efficacy and safety of cenobamate in patients with...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.